Clinician-Guided Weight Loss Program Pricing
Consultation with an independent licensed clinician required before starting a program with GLP-1 medications.
Semaglutide Program
Starter Plan
$149 per month
$399 - 3 months ($133/mo equivalent)
$699 - 6 months ($116/mo equivalent)
Semaglutide Starter Plan is a 6 month plan for new patients (.25mg, .5mg, 1mg, 1.5mg, 2mg, 2.5mg)
Any Dose Plan
$199 per month
$498 - 3 months ($166/mo equivalent)
$984 - 6 months ($149/mo equivalent)
$1,500 - 12 months ($125/mo equivalent)
Semaglutide Any Dose Plan includes any dose for patients on medication already (.25mg, .5mg, 1mg, 1.5mg, 2mg, 2.5mg)
Tirzepatide Program
Starter Plan
$249 per month
$699 - 3 months ($233/mo equivalent)
$1,299 - 6 months ($216/mo equivalent)
Tirzepatide Starter Plan is a 6 month plan for new patients (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg)
Any Dose Plan
$299 per month
$798 - 3 months ($266/mo equivalent)
$1,398 - 6 months ($233/mo equivalent)
$2,688 - 12 months ($224/mo equivalent)
Tirzepatide Any Dose Plan includes any dose for patients on medication already (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg)
A $20 clinician consultation is required at the time of the independent clinician visit.
All Programs Include
Medication
Supplies
Shipping
Included, but Participation Not Required:
Wellness Plan
Community Support Group
Nutrition Coaching
Meal Planning Support
Fitness App
Fitness Coaching
Accountability
Weekly Support Calls
© 2026. SimpleCare.
SimpleCare (Simple Life, LLC) does not practice medicine or sell prescription medication. Simple Care is a technology platform and referral partner offering access to a licensed physician network.The information provided on this website is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. SimpleCare provides access to a network of licensed healthcare professionals who provide telehealth consultations and medical evaluations. Healthcare services are provided by independent licensed clinicians who exercise their own clinical judgment in evaluating and treating patients. Prescription medications are provided only when deemed medically appropriate by a licensed healthcare provider following a clinical evaluation. Not all patients will qualify for treatment. Individual results may vary. Weight loss results depend on many factors including lifestyle, medical history, adherence to treatment, and other health conditions. All medications carry potential risks and side effects. Patients should discuss potential risks, benefits, and alternatives with their healthcare provider prior to beginning treatment. This website and its services are not intended for medical emergencies. If you are experiencing a medical emergency, call 911 or seek immediate medical attention. The products and statements discussed on this website—excluding prescription medications when true—have not been evaluated by the U.S. Food and Drug Administration (FDA).
Semaglutide, tirzepatide, and other GLP-1 receptor agonist medications may not be approved by the FDA for all uses discussed.
Important Notes:
-
*Compounded semaglutide is not FDA-approved and the FDA does not evaluate compounded products for safety, effectiveness, or quality. Ozempic® and Wegovy® are not compounded. Ozempic® and Wegovy® are both products and registered trademarks or Novo Nordisk A/S. Ozempic® is FDA-approved for type 2 diabetes but may be prescribed off-label for weight loss per a healthcare practitioner's discretion. Wegovy® has been approved by the FDA for diabetes and weight loss.
-
*Compounded tirzepatide is not FDA-approved and the FDA does not evaluate compounded products for safety, efficacy or quality. Mounjaro® is FDA-approved for type 2 diabetes and may be prescribed off-label for weight loss per a healthcare practitioner's discretion. Mounjaro® is a product and registered trademark of Eli Lily and Company.